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preHAARTHIV infection has a signiﬁcant impact on the natural progression of hepatitis B virus (HBV) related liver
disease. In HIV-HBV co-infected patients, little is known about mutations in the HBV genome, which can
inﬂuence severity of liver disease. The aim of this study was to characterize and to determine the frequency
of known clinically signiﬁcant mutations in the HBV genomes from HIV-HBV co-infected patients and from
HBV mono-infected patients. To accomplish this, genomic length HBV sequencing was performed in highly-
active anti-retroviral therapy (HAART)-naïve HIV-HBV co-infected patients (n=74) and in anti-HBV
therapy-naïve HBV mono-infected patients (n=55).
The frequency of HBV mutations differed between the co-infected and mono-infected patients when
comparing patients with the same genotype. BCP mutations A1762T and G1764A were signiﬁcantly more
frequent in HBV genotype C mono-infection and the -1G frameshift was signiﬁcantly more frequent in co-
infection and was only observed in HBV genotype A co-infection. PreS2 deletions were observed more
frequently in the setting of co-infection. Further work is needed to determine if these mutational patterns
inﬂuence the differences in liver disease progression in HIV-HBV co-infected and HBV mono-infected
patients.u (J. Audsley).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Co-infection with human immunodeﬁciency virus-1 (HIV) and
hepatitis B virus (HBV) is common due to shared routes of
transmission, with reported ﬁgures indicating approximately 10% of
33 million HIV-infected patients worldwide are chronically infected
with HBV (Kellerman et al., 2003; Konopnicki et al., 2005; Lincoln et
al., 2003; Ockenga et al., 1997; Thomas et al., 1994). HIV infection has
a signiﬁcant impact on the natural progression of HBV infection, with
increased levels of HBV DNA and an elevated risk of liver-associated
mortality (Colin et al., 1999; Gilson et al., 1997; Thio et al., 2002).However, an association of HIV co-infection with the emergence of
speciﬁc mutations in the HBV genome is not known.
A number of clinically signiﬁcant HBV genome mutations have
been reported in HBV mono-infection. A Precore stop codon
substitution at amino acid (aa) 28 (W28 stop, nucleotide (nt)
G1896A) is associated with failure to synthesize hepatitis B e antigen
(HBeAg) (Carman et al., 1989; Okamoto et al., 1994). In the basal core
promoter (BCP) region, two associated nt changes, A1762T and
G1764A have been associated with reduced Precore mRNA transcrip-
tion and reduced HBeAg production (Buckwold et al., 1996; Gunther
et al., 1998). These mutations also affect the X gene, due to
overlapping reading frames, resulting in substitutions in the X protein
at aa 130 and 131 (Funk et al., 2002; Moriyama et al., 1996; Okamoto
et al., 1994). Both the BCP A1762T/G1764Amutations and the Precore
stop codon mutation have been associated with advanced liver
540 J. Audsley et al. / Virology 405 (2010) 539–547disease including hepatocellular carcinoma (HCC) and cirrhosis in
mono-infected patients (Bläckberg and Kidd-Ljunggren, 2003; Chen
et al., 2007b; Lindh et al., 1999; Tong et al., 2007). Combinations of
these mutations, rather than the presence of a single mutation, have
had the strongest association with advanced liver disease and HCC
(Preikschat et al., 2002; Tanaka et al., 2006). Deletions in the PreS1
and PreS2 regions of the envelope gene and truncation of the S
proteins due to premature stop codons have been reported in mono-
infection (Bock et al., 1997; Chen et al., 2007a; Fang et al., 2008; Liu et
al., 2002; Mun et al., 2008; Song et al., 2005; Trautwein et al., 1996). In
addition, S proteins with truncations between aa positions 22 and 172
possess transactivational activity associated with an increased risk of
HCC (Lauer et al., 1992). S proteins with truncations after aa position
175 (within the 3rd hydrophobic domain) do not confer transactiva-
tional activity, but are retained intracellularly. Intracellular retention
of an additional envelope protein, the L protein, is associated with
severe liver disease (Bruss and Ganem, 1991). Finally, in HIV-HBV co-
infected patients with genotype A, we have recently described an HBV
mutant that encodes for truncated core and Precore proteins (-1G
mutant) (Revill et al., 2007). This mutant was associated with high
HBV DNA levels (Revill et al., 2007).
The aim of this study was to characterize HBV genome mutations
observed in HIV-HBV co-infected and HBVmono-infected patients. To
accomplish this, full genomic length HBV sequencing was performed
in an international cohort of highly-active anti-retroviral therapy
(HAART)-naïve HIV-HBV co-infected patients and anti-HBV therapy-
naïve HBVmono-infected patients to examine the type and frequency
of known clinically-signiﬁcant mutations.
Results
Study participants and clinical features
This study included 88 HIV-HBV co-infected and 64 HBV mono-
infected patients (Table 1). Statistically signiﬁcant differences
between HIV-HBV co-infected and HBV mono-infected patients
were observed for gender (more females in the mono-infected
patients, pb0.001), ethnicity (more Caucasians in the co-infected
patients, pb0.001) and HBeAg status (more HBeAg positive patients
in the co-infected patients, p=0.02). Median age of the co-infected
patients at the time of the preHAART sample was 37.2 years, age was
not available for the mono-infected patients. There was no difference
in the plasma HBV DNA (log10 IU/ml) between the groups (p=0.54).
Mixtures of more than one HBV genotype were identiﬁed in seven co-
infected samples but none of the samples from HBV mono-infected
patients. In the mixed genotype cases, the genome sequence
generated by direct sequencing was based on the predominant HBV
genotype. There was a signiﬁcant difference in the genotype
distribution between the co- and mono-infected patients when all
genotypes were included in a Chi-squared analysis (p≤0.001),
however in a series of pairwise analyses of genotypes A, B and C
there were no signiﬁcant differences in the prevalence. For the co-
infected patients, the median duration of HIV was 4.4 years, the major
transmission risk factor was sexual and the median CD4 nadir was 87
cells/μl. As the inclusion criteria for co-infected patients was pre-
HAART rather than anti-HBV therapy naïve, a small number of
patients had either past or current lamivudine (LMV) experience
(n=7) and past experience with pegylated interferon (n=2).
Phylogenetic analysis
Phylogenetic analysis was restricted to genomic length HBV
sequences only (co-infected n=74, mono-infected n=55). HBV has
been classiﬁed into 10 genotypes, A to J, based on nt sequence
diversity of at least 8% in the genome-length sequence (Tatematsu et
al., 2009). Within these genotypes, subgenotypes have been identiﬁedthat differ by between 4 and 7.5% at the nt level. The majority of
patients belonged predominantly to subgenotypes A2, B2, and C1
(Fig. 1). HBV sequences from eight mono-infected patients were
identiﬁed as subgenotype C2 and one as C5. In the co-infected
patients, one A1 and one A/D recombinant were identiﬁed. The
majority of C1 sequences isolated from co-infected patients in
Thailand formed a separate clade from the C1 sequences of mono-
infected patients from Hong Kong. However, the Hong Kong and Thai
HBV sequences only diverged by an average of 2.7% (not shown),
indicating they were the same subgenotype.
Clinically signiﬁcant mutations
We examined the frequency of the followingmutations in the HBV
genomes of the mono-infected and co-infected patients: BCP A1762T
and G1764A (reduced Precore mRNA transcription), Precore G1896A
(W28 stop, failure to synthesize HBeAg), Pre S1 and PreS2 deletions
(associated with accelerated disease progression in HBV mono-
infection), and the -1G frameshift (associated with HIV co-infection).
As some co-infected participants (n=7) were exposed to LMV, we
also examined the frequency of polymerase rt L180M and rt M204V
(signature LMV resistance mutations (Allen et al., 1998).
In both the co-infected and mono-infected patients, the BCP
A1762T and G1764A mutations were the most common mutations
(Table 2a) but were signiﬁcantly more frequent in the mono-infected
patients (p=0.02 and 0.01 respectively). The PreS2 deletions and -1G
frameshift were present in co-infected patients with a frequency of
14.6% and 10.8%, respectively; however these mutations were
uncommon in the mono-infected patients (3.3% and 0%, respectively).
PreS2 deletions were usually observed in combination with BCP
1762/4 mutations (Fig. 2). The proportions of G1896A, pol rt M204V,
pol rt L180M or PreS1 deletions were similar in both mono and co-
infected patients. None of the core or envelope deletions that have
been previously associated with HBV mono-infected patients on
immunosuppressive therapy were found in the co-infected or mono-
infected patients (Günther et al., 2000; Märschenz et al., 2006).
In order to determine whether the differences in frequencies of the
BCP A1762T, G1764A, PreS2 deletions and -1G frameshift between the
co-infected and mono-infected patients were inﬂuenced by genotype,
we compared the co-infected and mono-infected patients within each
HBV genotype (Table 2b). The frequency of BCP A1762T and G1764A
mutations was signiﬁcantly higher in HBV mono-infected patients
compared to co-infected patients with genotype C, but the frequency
was similar in patients with HBV genotype A. The -1G frameshift was
only present in genotype A co-infected patients, (pb0.001 for genotype
A compared to genotype B and C combined). The frequency of PreS2
deletionswas higher in HBV co-infected patientswith both genotypes A
and C, but did not reach statistical signiﬁcance.
Association of clinical and virological variables with the frequency of
HBV mutations
Multivariate Poisson regression analysis was performed combin-
ing the co-infected and mono-infected patients to determine if the
frequency of BCPmutations and amino acid substitutions in functional
domains (including the a determinant of the S protein) were
associated with any clinical and/or HBV parameters. The a determi-
nant contains the major antigenic region located within the S protein
(aa positions 110–160), with upstream and downstream regions
located at aa1–109 and aa161–226 respectively. Associations with
mutation frequency were identiﬁed for HBeAg positive status and
genotype. Positive HBeAg status was associated with a 0.3-fold
decrease in the frequency of mutations in the Precore gene, as well
as decreases in the BCP (0.7-fold), PreS1 (0.8-fold), and PreS2 (0.6-
fold) regions (Table 3a). In addition, lower mutation frequency in
association with HBeAg positive status was observed in the regions
Table 1
Demographics and clinical characteristics.
Characteristic Cohort group p
value
Co-
infection
Mono-
infection
Participants, n 88 63
Gendera, m/f 76/11 36/27 b0.001
Ethnicityb, n
Caucasian 46 0 b0.001
Asian 39 42
African 2 0
Not stated 1 21
Median age at sample date,
years (IQR)c
37.2 (32.1–43.6) – –
HBV genotype, n (%)
A 42 (47.7%) 13 (20.6%) 0.08
B 3 (3.4%) 17 (26.9%) 0.37
C 35 (39.7%) 33 (52.4%) 0.31
D 3 (3.4%) 0 –
G 5 0 –
A/Gd 5 – –
C/D 1 – –
C/G 1 – –
HBeAg status, positive/negative 44/39 15/41 0.02
Median (IQR) nadir CD4 count,
cells/μL
87 (33–222) – –
Median (IQR) HBV viral load, log10
IU/mL
7.25 (5.61–7.79) 7.20 (6.49–
8.15)
0.54
Median (IQR) HIV viral load at CD4
nadir, log10 copies/mL
4.87 (4.34–5.25) – –
Median duration of HIV at preHAART
sample date, years (IQR)
4.4 (0.4–9.5) – –
Risk factor for HIV/HBV – –
Sexual contact 79
Sexual contact and IDU 7
Unknown 2
IDU: intravenous drug use; IQR: inter-quartile range.
a Co-infection group also included one male-to-female transgendered individual.
b Includes Hispanic and non-Hispanic Caucasians.
c Age data were not available for the mono-infection group.
d For the analysis, mixed genotypes were reported according to the predominant
genotype present. Three of the A/G samples and the one C/G sample were
predominantly genotype G and the C/D sample predominantly genotype C. Two A/G
samples had equivalent amounts of the two genotypes, but the polymerase sequence
was predominantly genotype A, so were included as polymerase only genotype A
sequences.
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determinant.
Genotype B was associated with a 0.6-fold decrease in the number
of mutations in the region upstream of the a determinant and a 0.6-
fold decrease in PreS2. However, genotype C was associated with a
1.5-fold increase in mutation frequency in the BCP, a 1.7- and 2.3-fold
increase in mutations upstream or downstream of the a determinant
respectively, a three-fold increase in PreS1 mutations and a four-fold
increase in the number of mutations in the catalytic domain D region
of the HBV reverse transcriptase in Pol (pol rt D). HBVmono-infection
was associated with a 2-fold increase in the number of Precore
mutations and a 2.5-fold increase in pol rt D mutations.
We repeated this analysis, restricting it to the HIV-HBV co-infected
patients, to identify possible clinical factors associated with mutation
frequency in the setting of HIV-HBV co-infection. Only HBeAg status
and genotype were signiﬁcantly associated with the frequency of
mutations in the ﬁnal multivariate model (Table 3b), which included
the following additional HIV-related variables: HIV duration, pre-
HAART AIDS deﬁning illness, nadir CD4 and age at the preHAART
sample. Positive HBeAg status was associated with a decrease in the
frequency of mutations both upstream, within and downstream of the
S protein a determinant, (0.6-, 0.5- and 0.7-fold reductions,
respectively). HBV genotype A was signiﬁcantly associated with a 2-
fold increase in the number of PreS1mutations and HBV genotype C
with an increase in the number of mutations upstream, within, and
downstream of the S protein a determinant (1.7-, 2.4-, and 1.9-fold
increases respectively), and PreS1 region (3.5-fold).
Positive and negative selection in patients with HBV genotype C
While the total number of sites undergoing positive or negative
selection did not signiﬁcantly differ between the co-infected and
mono-infected patients with HBV genotype C (not shown), three
mutations were identiﬁed as under positive selection in the HIV-HBV
co-infected patients. One was located in the polymerase gene at aa rt
223 and two were located in the X gene (aa 30 and 47), one of which
overlapped with pol (RNaseH117=N HB X 47). None of these
mutations were located within known T-cell epitopes (Desmond et
al., 2008). No mutations undergoing positive selection were identiﬁed
in the HBV mono-infected patients. However, a total of 53 nucleotide
changes undergoing negative selection were identiﬁed in the co-
infected patients and 50 were identiﬁed in the HBV mono-infected
patients. Four codons undergoing negative selection in HIV-HBV co-
infected patients were located in known T-cell epitopes (Desmond et
al., 2008). These were at Core 23 (epitope at 18–27), RNaseH 66 in
polymerase (epitope at 63–71), PreS2 4 (epitope at 1–15), and surface
212 (epitope at 207–216). No mutations were identiﬁed in T-cell
epitopes of HBV mono-infected patients, although one mutation was
identiﬁed in the a determinant of the S protein (surface126).
Discussion
To our knowledge, this is the ﬁrst study to describe full HBV
genome sequences in a large cohort of HIV-HBV co-infected patients
prior to HAART and HBVmono-infected patients naïve to HBV therapy
to determine the frequency of clinically signiﬁcant mutations in both
settings. We compared the frequency of HBV mutations in HIV-HBV
co-infected and HBV mono-infected patients adjusted for HBV
genotype. Two BCP mutations were signiﬁcantly more common in
HBV from mono-infected patients with HBV genotype C. In addition,
in HIV-HBV co-infected patients, the -1G frameshift mutation was
signiﬁcantly more common, and was only observed in HBV genotype
A. HBV PreS2 deletions were more frequent in the setting of co-
infection, and this was not explained by differences in HBV genotypes
between the two groups.BCP A1762T and G1764A mutations were more common in
patients with HBV genotype C mono-infection, as previously
described in patients from Taiwan and China (Chen et al., 2005,
2007a,b; Du et al., 2007). These BCP mutations have been associated
with reduced Precore mRNA transcription and reduced HBeAg
production (Buckwold et al., 1996; Gunther et al., 1998). High
frequency of mutations in genotype C may be linked to the longer
duration of infection, however when comparing genotype B and C
Asian cohorts where all infections were likely acquired in the
perinatal period, genotype C was still associated with these mutations
suggesting that duration of infection was not the only explanation for
such ﬁndings in genotype C. BCP A1762T and G1764A have a reported
association with HCC in particular, and more severe clinical outcomes
in general (Bläckberg and Kidd-Ljunggren, 2003; Chen et al., 2005,
2007a,b; Du et al., 2007; Lindh et al., 1999; Tong et al., 2007).
The -1G frameshift mutation, which has been associated with HIV-
HBV co-infection and high levels of HBV DNA (Revill et al., 2007), was
only observed in samples from the co-infected patients with HBV
genotype A. This mutation results in a frameshift in the Precore/core
genes that truncates the deduced Precore and core proteins in a key T-
cell epitope (Revill et al., 2007). Unpublished data show that the
truncated proteins encoded by the -1G mutant accumulate in the
hepatocyte ER (Revill, unpublished) and the effect of this
Fig. 1.Unrooted neighbour-joining tree of all genomic-length HBV sequences from the total cohort. Bootstrap values (1000 replicates) are shown at selected nodes. The subgenotype
of major clades is indicated at the periphery of the tree. All sequences from HIV-HBV co-infected individuals are preﬁxed by “co” (shaded blue) and all sequences from HBV mono-
infected individuals are preﬁxed by “mo” (shaded red). Other abbreviations are as follows: Thai=Thailand, Vic=Victoria, Syd=Sydney, HK=Hong Kong. Reference sequences are
labelled as A1, A2 to G.
542 J. Audsley et al. / Virology 405 (2010) 539–547accumulation is currently under investigation. Previous studies of
HBV mono-infected renal transplant recipients on immunosuppres-
sive therapy observed deletion mutations in the Precore/Core region
of HBV (Günther et al., 2000; Märschenz et al., 2006). We did not
observe these deletions in the HBV sequences from co-infected
patients in our study.
PreS2 deletionsweremore frequent in co-infection, however there
was no signiﬁcant association with genotype. The majority of PreS2
deletions were located close to the N-terminus of the PreS2 protein.
HBV with mutations in PreS can accumulate in the endoplasmic
reticulum (ER) of hepatocytes during late stages of infection, causing
oxidative stress and the formation of ground glass hepatocytes (Fan et
al., 2001; Hsieh et al., 2004). Furthermore, in vitro studies have shown
that intracellular accumulation of the HBV large surface protein or
PreS1/PreS2 mutant proteins can induce ER stress, increase activation
of the HBV S promoter and alter HBV protein expression, increasenuclear factor-κB transcription and the over-expression of the COX-2
gene; which have been associated with increased cell cycle progres-
sion, oxidative stress and DNA damage (Hsieh et al., 2004;Wang et al.,
2003; Xu and Yen, 1996). Themajority of the PreS2mutants identiﬁed
in our study also encoded A1762T/G1764A basal core mutations. The
presence of PreS2 deletions together with BCP A1762T/G1764A
mutations have been reported in immunosuppressed genotype A HBV
mono-infected patients with advanced liver disease (Märschenz et al.,
2006). In that study the PreS2 deletion was located towards the C-
terminus (aa 140/141), whereas in our study the PreS2 deletions
were located towards the N-terminus. The PreS2 deletion mutants
near the C-terminus were found to have increased replication
phenotypes relative to wild-type virus (Märschenz et al., 2006).
Further studies are needed to determine if PreS2 deletions near the N-
terminus result in intracellular accumulation of aberrant envelope
proteins or have increased replication phenotypes.
Table 2a
Number (percentage) of individuals with mutations at reported clinically signiﬁcant
locations for co-infected and mono-infected individuals.
Location Co-infected Mono-infected p-value
Precore G1896A 9/75 (12.0) 9/57 (15.8) 0.53
BCP A1762T 33/83 (39.8) 35/59 (59.3) 0.02
BCP G1764A 33/83 (39.8) 36/59 (687.0) 0.01
pol rt L180M 1/87 (1.2) 1/63 (1.6) 0.82
pol rt M204V 2/87 (2.3) 0/63 (0.0) 0.23
PreS1 deletions 5/74 (6.8) 1/61 (1.6) 0.22
PreS2 deletions 12/82 (14.6) 2/60 (3.3) 0.04
-1G frameshift 8/74 (10.8) 0/55 (0.0) 0.02
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samples from the co-infected patients (who had all had prior
experience with LMV) and one sample from a mono-infected
individual who was treatment naive. It has been previously reported
that LMV-resistancemutations can occur naturally in treatment-naïve
patients with chronic HBV infection (Kirishima et al., 2002; Kobayashi
et al., 2001).
The HBV subgenotype distribution within the cohort conformed to
previously identiﬁed geographic distribution (Huy et al., 2004; Norder
et al., 2004). That is, most genotype A sequences were subtype A2, and
HBV sequences from Thailand and Hong Kong were predominantlyFig. 2. PreS deletions observed in the co-infection group. (a) Regions of the PreS sequence w
al., 2009; Chen et al., 2006, 2008; Fan et al., 2001; Preikschat et al., 2002). (b) Position of Pr
DNA regions shown at the top. Deletions are indicated by the interruption; the number prior
the interruption indicates the length of each deletion. The genotype for each sequence is sho
the same viral sequence. -1G=-1G frameshift mutation; sAg_/182*/183*/74* and 199*=
PreS2_M1V/T/I=mutation in HBV PreS2 at amino acid position 1, substitution of M (meth
HBV Core at amino acid position 183.subtype C1. Despite a high degree of sequence identity, the C1
sequences from Hong Kong and most of the sequences from Thailand
separated into different clades on the tree, indicative of their different
geographical origins (Huy et al., 2004).
A positive HBeAg status was associated with a decrease in
mutation frequency in both the total cohort and the co-infected
patients alone. Lower mutation counts in HBeAg positive patients has
been observed previously using different methodology and may be a
consequence of reduced immune pressure in HBeAg non-serocon-
verters (Lim et al., 2007). Whilst we detected a number of HBV
mutations in key immunological epitopes, overall the frequency of
mutations under selection pressure was low. This is consistent with
the low HBV-speciﬁc T-cell response observed in both HBV mono-
infection and HIV-HBV co-infection (Chang et al., 2005, 2007; Crane et
al., 2009). A number of mutations were identiﬁed undergoing
negative selection pressure, which supports previous ﬁndings that
negative selection predominates in HBV evolution (Osiowy et al.,
2006). The presence of a small number of codons under negative
selection within immunological epitopes in the core, polymerase and
envelope genes of the HIV-HBV co-infected patients implies func-
tional constraints on the encoded amino acids. Althoughwe identiﬁed
3 codons under positive selection in the HIV-HBV co-infected patients,
we did not identify positive selection in the HBV core/Precore gene as
previously reported in HBeAg seroconverters (Lim et al., 2007).here deletions have been predominantly detected previously in mono-infection (Abe et
eS deletions observed in the co-infection group. Mapping of the wild type preS1/preS2
to each deletion indicates the position in the PreS1 or preS2 gene and the number within
wn to the right with the presence of other clinically signiﬁcant mutations detected from
stop codon in HBV surface antigen at amino acid positions 182, 183 or 74 and 199;
ionine) for either V (valine), T (threonine) or I (isoleucine); Core_183*=stop codon in
Table 2b
Number and percentage of co-infected and mono-infected individuals with mutations
at previously reported clinically signiﬁcant locations according to genotype.
Co-infected Mono-infected
Location Number mutations by
genotype
Number mutations by
genotype
A B C A B C
n=42 n=3 n=35 n=13 n=17 n=33
BCP A1762T 15 0 17a 5 5 25a
(35.7%) (0%) (48.6%) (38.5%) (29.4%) (75.8%)
BCP G1764A 15 0 17b 5 5 26b
(35.7%) (0%) (48.6%) (38.5%) (29.4%) (78.8%)
PreS2 deletions 4 0 8 0 0 2
(9.5%) (0%) (22.8%) (0%) (0%) (6.1%)
-1G frameshift 8c 0 0 0 0 0
(19.0%) (0%) (0%) (0%) (0%) (0%)
a Statistically signiﬁcant for genotype C (p=0.008).
b Statistically signiﬁcant for genotype C (p=0.004).
c Statistically signiﬁcant for total genotype A compared to total genotype B combined
with total genotype C (p=0.001).
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cohorts were HBeAg negative, their anti-HBe status was unknown. In
addition, our study was restricted to HBV genotype C, whereas Lim
et al studied HBV genotype B (Lim et al., 2007). It was not possible to
measure evolution rates in this cross-sectional study. However,
longitudinal samples available from this cohort will enable us to
address this in future studies.
It is surprising that we did not observe a statistically signiﬁcant
difference in HBV DNA level between the mono- and co-infected
patients. HBV DNA is generally higher in co-infection (Colin et al.,
1999; Gilson et al., 1997), however these studies were conducted in
cohorts of European origin and therefore likely to be HBV genotype A
or D, not C. In addition, it is well described that HBV DNA levels are
higher in HBeAg positive patients (Fattovich et al., 2008), and the co-
infected group had a higher percentage of HBeAg positive patients.
The lack of difference in our study may be due to the predominance of
genotype C patients in both groups. Similar cohorts have not been
examined previously.
This study had a number of limitations. Direct comparisons
between the mono-infected and co-infected patients are inherently
problematic due to different genotype distribution in the groups.
Patients with HBV genotype C from Asia are much more likely to have
acquired their HBV by perinatal transmission. They are thereforemore
likely to have a longer duration of HBV infection, resulting in a longer
time period for mutations to accumulate and for virus evolution. In
contrast, patients infected with HBV genotype A in Western countries
are much more likely to have acquired their HBV infection as adults
through sexual contact or exposure to contaminated blood; hence
their duration of HBV infection will be shorter. However, in this study
these potential differences were minimised since genotype-speciﬁc
analyses were performed, genotype was an independent variable at
the multivariate level and analysis of positive and negative selection
was only completed for patients with HBV genotype C, where there
were approximately equal numbers in the mono-infected and co-
infected patients. Age data and risk factors for HBV infection were not
available for the mono-infected patients. Although the co-infected
genotype C participants were recruited from Thailand and the mono-
infected from Hong Kong, the subgenotype distribution in the Asian
patients (Thailand and Hong Kong) was similar, with B2 and C1
subgenotypes predominant. Another limitation was the use of
different HBV DNA assays. However, all HBV DNA results were
converted into the standard international units for comparison, which
should limit assay variability. HBV DNA comparisons between the
mono-infected and co-infected patients may have been affected by
the in-house assay used for quantitation of samples from participantsin Hong Kong (n=42). In a subset of 11 patients from Hong Kong, the
plasma HBV DNA was repeated using the commercial RealArt HBV
Light Cycler PCR assay, and the two sets of results were similar. Finally,
as a cross sectional study, we only assessed a single sample from each
individual and therefore could not evaluate rates of mutation
evolution.
In conclusion we found two major differences in the frequency of
HBV mutations in co-infection and mono-infection, even when only
comparingpatientswith the samegenotype. BCPmutationsA1762T and
G1764Aweremore frequent inHBV genotypeCmono-infection and the
-1G frameshift was only observed in HBV genotype A co-infection. In
addition, PreS2 deletions were more common in co-infected patients.
Further work is needed to determine the effect of these mutations on
hepatocyte pathology. These co-infected patients are being followed
prospectively to determine any relationship between these preHAART
HBV mutations and disease progression.
Subjects and methods
Study participants
This study included a total of 151 patients, 88 who were HIV-HBV
co-infected and 63 HBV mono-infected, who were recruited from
October 2004 to September 2008. Co-infected patients were recruited
from sites in Australia, the United States (US) and Thailand; and
mono-infected patients were recruited from sites in Australia and
Hong Kong. Inclusion criteria for the cohort included documented
chronic HBV infection (presence of hepatitis B surface antigen
(HBsAg) on two occasions a minimum of 6 months apart); and HCV
negative, which was deﬁned as HCV antibody (anti-HCV) negative or
anti-HCV positive and HCV RNA negative. For patients who were anti-
HCV negative with a CD4 countb200 cells/μl, HCV RNA was tested
regardless of anti-HCV status to look for occult hepatitis C (Bonacini
et al., 2001). Additional inclusion criteria for the co-infected patients
were documented positive HIV antibody, HAART-naïve (deﬁned as a
minimum of three antiretrovirals from at least two different classes),
and a stored serum sample prior to the initiation of HAART. For the
mono-infected patients, documented negative HIV antibody was
required as well as being naïve to any anti-HBV medication. Written,
informed consent was obtained from all participants, and the study
was approved by the relevant Human Research Ethics Committees in
Australia, the United States, Thailand and Hong Kong.
HBV DNA quantiﬁcation
HBV DNA quantiﬁcation at all sites, except Hong Kong, was
performed using either the HBV Digene Hybrid Capture II microplate
assay (Roche, Branchburg, N.J.; lower limit of detection (LLOD)
2.3×104 IU/mL), the Versant HBV DNA 3.0 assay (Bayer HealthCare-
Diagnostics, Tarrytown, N.Y.; LLOD 357 IU/mL), or the RealARTTM HBV
LC PCR (QIAGEN), LLOD 20 IU/ml in accordance with the manufac-
turer's instructions. HBV DNA quantiﬁcation in Hong Kong was
determined using an in-house Taqman PCR assay, which ampliﬁed the
HBV core region (linear range 1×102 - 1×109 copies/ml). All results
were converted into international units for analysis.
HBV sequencing
HBV DNA was extracted from 200 μL of serum using the semi
automated Roche MagNA Pure System (version 2.1, Roche, Branch-
berg, NJ), performed according to the operators manual. Extracted
DNA was eluted in a ﬁnal volume of 50 μL of supplied elution buffer.
Full-genome HBV sequences were ampliﬁed and sequenced as
previously described (Gunther et al., 1995). Full genomic sequences
could not be ampliﬁed from sampleswith lowHBVDNA, inwhich case
we used alternate primers to amplify the HBV polymerase (pol)
(Ayres et al., 2004). HBV consensus sequences were constructed using
the DNA sequence analysis program SeqScape (ABI Prism, Applied
Table 3a
Multivariate Poisson regression analysis of clinical parameters associated with various HBV genome region mutations in the total cohort (co-infected and mono-infected patients).
Statistically signiﬁcant (pb0.05) or near signiﬁcant results only.
HBV region Variable Univariate analysis Multi-variate analysis
Poisson co-effa 95% CI p-value Poisson co-eff 95% CI p-value
Precore HBeAg+ve −1.2 −1.74, −0.67 b0.001 −1.33 −1.89, −0.79 b0.001
HBV mono-infection 0.49 −0.02, 1.00 0.058 0.72 0.20, 1.24 0.007
BCP HBeAg positive −0.42 −0.62, −0.22 b0.001 −0.36 −0.57, −0.16 0.001
HBV Genotype C 0.43 0.23, 0.63 b0.001 0.41 0.20, 0.62 b0.001
Upstream (aa1–109) of the a determinant of S protein HBeAg positive −0.59 −0.81, −0.37 b0.001 −0.48 −0.71, −0.26 b0.001
HBV Genotype B −0.94 −1.42, −0.47 b0.001 −0.61 −1.11, −0.10 0.019
HBV Genotype C 0.76 0.53, 0.98 b0.001 0.51 0.26, 0.76 b0.001
downstream (aa161–226) of the a determinant of S protein HBeAg positive −0.45 −0.66, −0.24 b0.001 −0.33 −0.55, −0.12 0.002
HBV Genotype C 0.96 0.68, 1.12 b0.001 0.84 0.61, 1.07 b0.001
Pol rt D Mono-infection 1.08 0.32, 1.83 0.005 0.91 0.15, 1.66 0.019
HBV Genotype C 1.63 0.74, 2.52 b0.001 1.52 0.62, 2.41 0.001
Env PreS1 HBeAg positive −0.39 −0.55, −0.23 b0.001 −0.27 −0.43, −0.10 0.002
HBV Genotype A −0.29 −0.48, −0.11 0.002 0.69 0.37, 1.00 0.001
HBV Genotype C 0.74 0.57, 0.90 b0.001 1.12 0.84, 1.40 b0.001
Env PreS2 HBeAg positive −0.49 −0.69, −0.29 b0.001 −0.46 −0.66, −0.25 b0.001
HBV Genotype B −0.54 −0.89, −0.19 0.002 −0.49 −0.84, −0.14 0.006
CI=conﬁdence interval.
We examined the relationship between mutation count in HBV and multiple clinical parameters. The speciﬁc regions of the HBV genome included terminal protein; spacer; pol RT F,
A, B, C, and E domains; interdomain; RNAse H; envelope PreS1 and PreS2; upstream and downstream of the a determinant region of the surface protein; the a determinant region of
the surface protein, epsilon; enhancer II; glucocorticoid responsive element, basal core promoter, preCore and core regions and the X protein. Regulatory elements including the
promoter sequences, core upstream regulatory sequence, direct repeats 1 and 2, enhancer I, enhancer I modulator, enhancer I central and X promoter were not analysed as all such
sequences were wild type in this cohort.
The clinical parameters included gender, HBeAg status, HBV DNA level, and HBV genotype.
a A negative Poisson co-efﬁcient indicates a decrease in the number of mutations, and a positive co-efﬁcient indicates an increase.
545J. Audsley et al. / Virology 405 (2010) 539–547Biosystems, Foster City, CA). HBV genotype and unique HBV
mutations were identiﬁed using a web-based analysis program,
SeqHepB (www.seqhepb.com), as previously described (Bartholo-
lomeusz et al., 2004; Yuen et al., 2007).
In cases where the sequencing revealed mixed HBV genotypes, we
determined the constituents of these genotype mixtures using an
INNO-LiPA HBV genotyping assay (Innogenetics, Gent, Belgium).Phylogenetic analysis
The HBV genomic length sequences obtained from the HIV-HBV
co-infected (n=74) and HBV mono-infected (n=55) patients were
aligned using Clustal X (Thompson et al., 1997) and MegAlign
(Clewley and Arnold, 1997) and edited using Bioedit and EditSeq
(Arnold and Clewley, 1997). Neighbour-joining phylogenetic trees
were constructed using the Phylip Seqboot, DNADist/ProtDist,
Neighbour and Consense programs (http://evolution.gs.washington.
edu/phylip.html) (Revill et al., 2007). The resultant neighbour-joining
tree was evaluated by bootstrap resampling with 1000 replicates andTable 3b
Multivariate Poisson regression analysis of clinical parameters associated with various HBV g
near signiﬁcant results only.
HBV region Variable Univa
Poiss
Upstream (aa1–109) of the a determinant of S protein HBeAg positive −0.6
HBV Genotype C 0.6
a determinant of S protein HBeAg positive −0.8
HBV Genotype C 0.8
Downstream (aa161–226) of the a determinant of S protein HBeAg positive −0.5
HBV Genotype C 0.9
Env PreS1 HBV Genotype A −0.3
HBV Genotype C 0.7
CI=conﬁdence interval.
We examined the relationship between mutation count in HBV and multiple clinical paramet
A, B, C, and E domains; interdomain; RNAse H; envelope PreS1 and PreS2; upstream and dow
the surface protein; epsilon; enhancer II; glucocorticoid responsive element, basal core pro
promoter sequences, core upstream regulatory sequence, direct repeats 1 and 2, enhancer I,
sequences were wild type in this cohort.
The clinical parameters included gender, HBeAg status, HBV DNA level, genotype, HIV dura
a A negative Poisson co-efﬁcient indicates a decrease in the number of mutations, and atrees were edited using Treeview (Page, 1996) and Figtree (http://
tree.bio.edu.ac.uk/software/ﬁgtree). Sequence identity was deter-
mined using MegAlign (Clewley and Arnold, 1997). The following
reference sequences for each HBV genotype and subtype were
obtained from GenBank: A1 M57663; A2 X02763; A3 AB194951; A4
AM18062; A5; B1 D00329; B2 AF121249; B3 M54923; B4 AY033072;
B5 AB219429; C1 AY057947; C2 AY217378; C3 X75665; C4
AB048705; C5 AB241111. D2 Z35716; D3 J02203; D4 AB033559; F1
AY179735; G AB056515; H AY090460. Our classiﬁcation of HBV
subgenotype C was based on the method of Huy et al. (2004).
Recombinant HBV sequences were identiﬁed using SimPlot (Lole
et al., 1999).Positive and negative selection
Positive and negative selection was analysed using the HyPhy
program (www.datamonkey.org) using alignments generated in
Clustal X from patients infected with HBV genotype C. Positiveenome region mutations in the co-infected patients. Statistically signiﬁcant (pb0.05) or
riate analysis Multi-variate analysis
on co-effa 95% CI p-value Poisson co-eff 95% CI p-value
5 −0.94, −0.36 b0.001 −0.52 −0.82, −0.22 0.001
9 0.41, 0.97 b0.001 0.51 0.21, 0.80 b0.001
1 −1.28, −0.35 0.001 −0.66 −1.10, −0.18 0.007
2 0.39, 1.25 b0.001 −0.32 −0.61, −0.03 0.032
3 −0.81, −0.25 b0.001 −0.32 −0.61, −0.03 0.032
5 0.67, 1.23 b0.001 0.86 0.57, 1.16 b0.001
9 −0.61, −0.18 b0.001 0.67 0.21, 1.13 0.005
0 0.49, 0.90 b0.001 1.24 0.79, 1.68 b0.001
ers. The speciﬁc regions of the HBV genome included terminal protein; spacer; pol RT F,
nstream of the a determinant region of the surface protein; the a determinant region of
moter, preCore and core regions and the X protein. Regulatory elements including the
enhancer I modulator, enhancer I central and X promoter were not analysed as all such
tion, preHAART AIDS deﬁning illness, nadir CD4 and age at the preHAART sample.
positive co-efﬁcient indicates an increase.
546 J. Audsley et al. / Virology 405 (2010) 539–547selection occurs when an aa alteration confers a selective advantage
(adaptation), whereas negative selection is the elimination of aa
alterations that confer a disadvantage. Amino acids can also be altered
purely by chance (neutral selection). Positive and negative selection
can be estimated using codon-basedmodels that estimate the relative
amounts of synonymous (dS) and non-synonymous (dN) mutations
in different populations of sequences. If dN is greater than dS, the
sequences are undergoing positive selection, i.e., the mutation has
increased the ﬁtness of the sequence. Conversely, if dS is greater than
dN, the sequences are undergoing negative selection to remove
deleterious sequences from the gene pool. Datamonkey (www.
datamonkey.org, (Pond and Frost, 2005) is a web based engine that
enables analysis of positive and negative selection in aligned
sequences using the HyPhy program (Pond et al., 2005). HyPhy
enables statistical comparison of the number of synonymous and non-
synonymous mutations at each site in an aligned group of sequences.
To enable comparison of the degree of positive and negative selection
in HBV sequences from HIV-HBV co-infected and HBV mono-infected
patients we analysed separate alignments of each individual reading
frame (core, precore, polymerase, envelope and X) from co-infected
and mono-infected sequences, using the single likelihood ancestor
counting (SLAC) and ﬁxed effects likelihood (FEL) algorithms (Pond et
al., 2005). Brieﬂy, SLAC is a rapid method that enables detection of
non-neutral selection, based on the Suzuki–Gojobori counting
approach. FEL by contrast is a likelihood based method that ﬁts an
independent dN and dS to every site and tests whether dN≠dS
(Kosakovsky Pond and Frost, 2005; Pond et al., 2005). Only sites that
were identiﬁed by both the SLAC and FEL algorithms (p≤0.01
signiﬁcance) were included in the ﬁnal result. In our study, analysis
was restricted to sequences from patients infectedwith HBV genotype
C, since this was the most frequent genotype in the cohort and
because there were similar numbers of HIV-HBV co-infected (n=33)
and mono-infected (n=29) patients infected with genotype C.
Statistical methods
Categorical variables were compared using the Chi-square test, or,
where cell numbers were small, Fishers Exact test. Continuous
variables were compared using the Wilcoxon Rank Sum test. Data
from the co-infected patients were compared with the data from the
mono-infected patients, and where statistically signiﬁcant differences
were found the data was subgrouped by genotype and the analysis
was repeated to examine genotype effect. Poisson regression analysis
at the univariate and multivariate levels was used to investigate
predictors of the number of mutations per HBV genome region.
Univariate Poisson regression was used to identify candidate
predictors for inclusion in the multivariate model. The ﬁnal model
for each analysis was derived through a process of backwards
elimination where non-signiﬁcant variables were sequentially re-
moved until a subset was left with wholly signiﬁcant predictors.
Overall model ﬁt was assessed using a Goodness of Fit Pearson Chi
Square test. In all analyses pb0.05 was considered signiﬁcant. Poisson
regression is a log-linear model, with the polarity of raw Poisson co-
efﬁcients providing an indication of either an increase or decrease in
the count data for each outcome. The co-efﬁcients must be
exponentiated to obtain the linear equivalent of the increase or
decrease. The raw co-efﬁcients are presented in the tables, and the
exponentiated factor increases or decreases of signiﬁcant outcomes
are provided in the results section. Analysis was completed using
STATA software (Version 10.1, StataCorp, TX, USA).
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